MedLabs licenses the exclusive rights to manufacture and distribute the drug to Sino Pharm, a leading Chinese pharmaceutical company. In China the licensing agreement stipulates quality control measures and specifies that SinoPharm must obtain regulatory approval in China before market launch. However, SinoPharm allegedly fails. Adhere to the quality control standards set by Medlabs. Additionally, SinoPharm launches the drug without obtaining the necessary regulatory approvals, leading to product recalls and regulatory action against the company. Questions: 1) Did SinoPharm breach the licensing agreement by failing to comply with the quality control standards and regulatory requirements? 2) Did SinoPharm infringe on MedLabs' rights by launching the drug without authorization? 3) Can MedLabs terminate the licensing agreement due to SinoPharm's alleged breaches? 4) What are the different legal options for raising capital for an organization, and what are the key considerations for each option? 5) When forming a licensing agreement, what are the essential elements I should include to ensure clarity and protection for both parties involved